Lundbeck and Otsuka are working together on a vaccine to combat Alzheimer’s disease. This would be the duo’s third Alzheimer’s collaboration, and the agreement tethers the companies through Phase I.
This effort is an anti-beta amyloid vaccine that the companies expect would be used in the elderly. The companies said in a statement that the idea behind the treatment is that it could preserve cognitive function by preventing amyloid-beta deposits from accumulating.
The companies will decide next steps when Phase I ends. They expect the study to start next year.